Reuters logo
BRIEF-Array Biopharma presents full results from Phase 3 NEMO study
2016年6月6日 / 晚上6点26分 / 1 年前

BRIEF-Array Biopharma presents full results from Phase 3 NEMO study

June 6 (Reuters) - Array Biopharma Inc :

* Array presents full results from Phase 3 NEMO study

* Study found binimetinib significantly extended median progression-free survival, at 2.8 months, versus 1.5 months observed with dacarbazine

* Binimetinib also demonstrated significant improvement in overall response rate and disease control rate

* “We plan to submit our regulatory filing for binimetinib in NRAS -mutant melanoma later this month” Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below